HYDREIGHT TECHNOLOGIES Aktie

Hydreight reported a record quarter with CAD 28 million in revenue (+420% y/y) and profitability, but missed consensus on adjusted EPS (0.0499 $ vs. 0.0549 $) and revenue (27.39 Mio. $ vs. 30.93 Mio. $). Gross margin fell to 19.4% due to a stronger pharmacy business and pricing pressure, while adjusted EBITDA was CAD 3.2 million. Management reiterated the full-year guidance of CAD 150 million in revenue and an adjusted EBITDA margin of 15–17%, but requires a significantly stronger second half. » Mais em de.investing.com

Hydreight Technologies reported revenue of CAD 24.9 million for the first quarter of 2026, a 450% increase year over year, and reaffirmed annual guidance of at least CAD 150 million. The company attributed the growth to the rollout of the VSDHOne platform and the expansion of its pharmacy network. Gross margin fell to 20% with a gross profit of CAD 5.1 million, while operating expenses remained stable despite the revenue jump; adjusted EBITDA was CAD 3.3 million. The stock rose 11.56% after the announcement, and management cited regulatory developments and new product categories as growth drivers while noting risks such as competition and margin pressure. » Mais em de.investing.com

Hydreight Technologies reported a 132% revenue increase to $12.83 million in the third quarter of 2025 and its fourth profitable quarter in a row, but saw its share price drop 14.96% to $4.88. The company held $18.64 million in cash at quarter-end and posted a year-to-date margin of 28.21%. For 2026 Hydreight forecasts revenue between CAD 90.8 million and CAD 130 million, plans to expand its treatment offerings, is exploring AI integration and a possible uplisting to the NASDAQ. » Mais em de.investing.com